Courier and Laboratory Responsibilities in Chain of Custody Compliance

Introduction: The Custody Continuum Beyond the Site

While clinical investigators and site staff are responsible for the initial collection and custody of trial samples, the integrity of those samples depends equally on downstream stakeholders—namely, the couriers who transport them and the laboratories that receive and analyze them. Maintaining regulatory compliance during this transition requires precise role definitions, validated handover procedures, and documented accountability from point of collection to final analysis.

This article outlines the defined responsibilities of couriers and laboratories in the chain of custody documentation process. It draws from real-world FDA and EMA inspection findings and includes CAPA strategies to prevent sample loss, temperature excursions, and documentation failures across transport and laboratory intake.

Regulatory Expectations for Third-Party Handling of Clinical Samples

According to ICH GCP (E6 R2), all parties handling clinical samples—including outsourced logistics providers and laboratories—must operate under written procedures and quality systems that comply with regulatory standards. Sponsors are responsible for ensuring that these third parties are trained, qualified, and monitored. Specific expectations include:

• FDA 21 CFR 58.130(e): Requires records of the receipt and condition of samples, including chain of custody documentation.
• EMA GCP Module VI: Emphasizes documented traceability for human biological samples transported and analyzed off-site.
• ISO 17025 & 15189: Require lab intake procedures and custody logs for regulated testing.

Courier Responsibilities in Sample Transfers

Couriers act as the intermediary in clinical sample transfers. Their role is critical in preserving the cold chain, ensuring documentation accuracy, and enabling traceability.

• Pick-up from clinical site with signed custody forms
• Temperature-controlled packaging and transport
• Real-time tracking of shipment and environmental conditions
• Immediate notification to site/sponsor upon delay or excursion
• Hand-delivery to lab intake personnel with counter-signature
• Return of completed chain of custody documents to sponsor or designated repository

Couriers must be trained in sample handling SOPs and IATA DGR (Dangerous Goods Regulations). Sponsors are expected to qualify couriers through audits, CAPA review, and transport simulations for high-risk samples.

Laboratory Responsibilities Upon Sample Receipt

Laboratories are responsible for verifying sample integrity, reconciling shipments against manifests, documenting the receipt process, and reporting any discrepancies or condition issues. Key responsibilities include:

• Matching received samples to manifest and custody log
• Recording condition of samples (temperature, labeling, integrity)
• Assigning internal tracking IDs for downstream analysis
• Archiving transport documents for regulatory inspections
• Raising deviation reports if discrepancies are observed

Laboratories must have SOPs that cover sample reception, reconciliation, storage, and documentation aligned with ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate).

Case Study 1: Discrepancy in Courier Logs Leads to Data Invalidation

During a Phase II trial, a courier shipped biological samples from two clinical sites to a central lab using the same outer packaging but without site-level segregation. At the lab, several vials were unlabeled or mixed, making subject identification impossible.

Root Cause: Absence of courier SOPs for site-specific segregation and labeling.

CAPA Actions:

• Mandatory use of site-specific secondary containers for multi-site shipments
• Courier training on sample packaging hierarchy
• Chain of custody forms redesigned to include sender and courier field identifiers

Case Study 2: Lab Fails to Report Temperature Excursion

A central lab received a batch of frozen samples with internal data loggers showing a sustained temperature of -8°C (instead of the required -20°C). The intake staff failed to escalate the issue, and the samples were analyzed. During inspection, the FDA flagged the finding as a data integrity lapse.

Root Cause: No SOP for reviewing temperature logs during intake.

CAPA Actions:

• Revised intake SOP to include mandatory log review and documentation
• Staff retraining and role-based deviation escalation chart
• Retrospective deviation entry and notification to sponsor

Sample Custody Flow: Courier to Lab Handover Protocol

Best Practices for Sponsors and Monitors

• Include courier and lab oversight in trial risk assessment plans
• Audit all transport vendors for GCP compliance annually
• Use sample shipping KPIs (e.g., on-time delivery, deviations)
• Ensure CAPA closure before allowing continued use of noncompliant couriers or labs
• Incorporate sample transfer deviations in monitoring reports

External Reference

For guidance on the responsibilities of all clinical trial stakeholders, consult Canada’s Clinical Trials Database for relevant transport and custody inspection data.

Conclusion

As clinical trials become increasingly global and complex, the handover of clinical samples from site to courier to laboratory introduces significant compliance risk. Each stakeholder in the chain of custody must be held accountable for their specific responsibilities, guided by SOPs, training, and documented practices. CAPA systems must not only address individual lapses but drive long-term improvements across the custody continuum. Sponsors play a central role in ensuring that all parties are inspection-ready, well-trained, and aligned with global GCP expectations.